Intestinal Stem Cells (ISCs) derived from a patient's own cells have garnered significant attention as a new alternative for treating intractable intestinal diseases due to their low risk of rejection ...
Galit Meshulam-Simon is the associate director of Commercial Applications at Elegen. COVID-19 brought messenger RNA (mRNA) into the global spotlight, demonstrating its speed, flexibility, and efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback